In Silico Pharmacology最新文献

{"title":"Predicting phase-I metabolism of piceatannol: an in silico study","authors":"R. Rajan, Maida Engels, M. Ramanathan","doi":"10.1007/s40203-024-00228-x","DOIUrl":"https://doi.org/10.1007/s40203-024-00228-x","url":null,"abstract":"","PeriodicalId":13380,"journal":{"name":"In Silico Pharmacology","volume":"11 49","pages":"1-17"},"PeriodicalIF":0.0,"publicationDate":"2024-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141265487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring isoindolin-1-ones as potential CDK7 inhibitors using cheminformatic tools","authors":"Chahat Arora, Kunal Madaan, Saurabh Mehta, Ram Singh","doi":"10.1007/s40203-024-00225-0","DOIUrl":"https://doi.org/10.1007/s40203-024-00225-0","url":null,"abstract":"","PeriodicalId":13380,"journal":{"name":"In Silico Pharmacology","volume":"65 11","pages":"1-21"},"PeriodicalIF":0.0,"publicationDate":"2024-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141268279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigation of alpha amylase inhibitors from Bidens pilosa L. by in silico and in vitro studies","authors":"Akshay Galagali, Vishal S. Patil, Kashinath Hiremath, Ganesh H. Sampat, Rajlaxmi Patil, Rajashri Virge, Darasaguppe R. Harish, Harsha V. Hedge, Subarna Roy","doi":"10.1007/s40203-023-00187-9","DOIUrl":"https://doi.org/10.1007/s40203-023-00187-9","url":null,"abstract":"","PeriodicalId":13380,"journal":{"name":"In Silico Pharmacology","volume":"28 5","pages":"1-15"},"PeriodicalIF":0.0,"publicationDate":"2024-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139683079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Network pharmacology reveals the potential of Dolastatin 16 as a diabetic wound healing agent.","authors":"Dewi Luthfiana, Didik Huswo Utomo","doi":"10.1007/s40203-023-00161-5","DOIUrl":"10.1007/s40203-023-00161-5","url":null,"abstract":"<p><p>Dolastatin 16, a marine cyclic depsipeptide, was initially isolated from the sea hare <i>Dolabella Auricularia</i> by Pettit et al. Due to the lack of information regarding its bioactivity, target identification becomes an indispensable strategy for revealing the potential targets and mechanisms of action of Dolastatin 16. Network pharmacology was utilized to identify targets associated with the disease, gene ontology, and KEGG pathways. The results highlighted Matrix Metalloproteinase-9 (MMP9) as a potential target of Dolastatin 16 through network pharmacology analysis. This target was found to be primarily involved in the TNF signaling pathway and in foot ulceration-associated diabetic polyneuropathy. Furthermore, the binding mode and dynamic behavior of the complex were investigated through molecular docking and molecular dynamics studies. In the docking study, a native ligand (a hydroxamate inhibitor) and (R)-ND-336 were employed as ligand controls, demonstrating binding energy values of - 6.6 and - 8.9 kcal/mol, respectively. The Dolastatin 16 complex exhibited a strong affinity for MMP9, with a binding energy value of - 9.7 kcal/mol, indicating its high potential as an inhibitor. Molecular dynamics also confirmed the stability of the MMP9-Dolastatin complex throughout the simulation process. Dolastatin 16 has the potential to act as an MMP9 inhibitor, offering promise for accelerating the wound healing process in diabetic foot conditions.</p><p><strong>Supplementary information: </strong>The online version contains supplementary material available at 10.1007/s40203-023-00161-5.</p>","PeriodicalId":13380,"journal":{"name":"In Silico Pharmacology","volume":"11 1","pages":"23"},"PeriodicalIF":0.0,"publicationDate":"2023-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10504231/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10309187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"RND pump inhibition: in-silico and in-vitro study by Eugenol on clinical strain of <i>E. coli</i> and <i>P. aeruginosa</i>.","authors":"Elham Etesami Ashtiani, Zohreh Gholizadeh Siahmazgi, Mirsasan Mirpour, Bahram Mohammad Soltani","doi":"10.1007/s40203-023-00159-z","DOIUrl":"10.1007/s40203-023-00159-z","url":null,"abstract":"<p><p>Multidrug-resistant (MDR) gram-negative bacteria pose significant challenges to the public health. Various factors are involved in the development and spread of MDR strains, including the overuse and misuse of antibiotics, the lack of new antibiotics being developed, and etc. Efflux pump is one of the most important factors in the emergence of antibiotic resistance in bacteria. Aiming at the introduction of novel plant antibiotic, we investigated the effect of eugenol on the <i>MexA</i> and <i>AcrA</i> efflux pumps in <i>Pseudomonas aeruginosa</i> (<i>P. aeruginosa</i>) and <i>Escherichia coli</i> (<i>E. coli</i>). Molecular docking was performed using PachDock Server 1.3. The effect of eugenol on bacteria was determined by disk diffusion, minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC). A cartwheel test was also performed to evaluate efflux pump inhibition. Finally, the expression of the <i>MexA</i> and <i>AcrA</i> genes was examined by real-time PCR. The results of molecular docking showed that eugenol interacted with <i>MexA</i> and <i>AcrA</i> pumps at - 29.28 and - 28.59 Kcal.mol^-1, respectively. The results of the antibiogram test indicated that the antibiotic resistance of the treated bacteria decreased significantly (<i>p</i> < 0.05). The results of the cartwheel test suggested the inhibition of efflux pump activity in <i>P. aeruginosa</i> and <i>E. coli</i>. Analysis of the genes by real-time PCR demonstrated that the expression of <i>MexA</i> and <i>AcrA</i> genes was significantly reduced, compared to untreated bacteria (<i>p</i> < 0.001). The findings suggest, among other things, that eugenol may make <i>P. aeruginosa</i> and <i>E. coli</i> more sensitive to antibiotics and that it could be used as an inhibitor to prevent bacteria from becoming resistant to antibiotics.</p>","PeriodicalId":13380,"journal":{"name":"In Silico Pharmacology","volume":"11 1","pages":"22"},"PeriodicalIF":0.0,"publicationDate":"2023-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10425304/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10019893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Target validation and structure-based virtual screening to Discover potential lead molecules against the oncogenic NSD1 histone methyltransferase.","authors":"Zahid Rafiq Bhat, Anuj Gahlawat, Navneet Kumar, Nisha Sharma, Prabha Garg, Kulbhushan Tikoo","doi":"10.1007/s40203-023-00158-0","DOIUrl":"10.1007/s40203-023-00158-0","url":null,"abstract":"<p><p>The aim of the study was to validate Nuclear receptor-binding SET Domain NSD1 as a cancer drug target followed by the design of lead molecules against NSD1. TCGA clinical data, molecular expression techniques were used to validate the target and structure-based virtual screening was performed to design hits against NSD1. Clinical data analysis suggests the role of NSD1 in metastasis, prognosis and influence on overall survival in various malignancies. Furthermore, the mRNA and protein expression profile of NSD1 was evaluated in various cell lines. NSD1 was exploited as a target protein for in silico design of inhibitors using two major databases including ZINC15 and ChemDiv by structure-based virtual screening approach. Virtual screening was performed using the pharmacophore hypothesis designed with a protein complex S-adenosyl-l-methionine (SAM) as an endogenous ligand. Subsequently, a combined score was used to distinguish the top 10 compounds from the docking screened compounds having high performance in all four scores (docking score, XP, Gscore, PhaseScreenScore, and MMGBSA delta G Bind). Finally, the top three Zinc compounds were subjected to molecular dynamic simulation. The binding MMGBSA data suggests that ZINC000257261703 and ZINC000012405780 can be taken for in vitro and in vivo studies as they have lesser MMGBSA energy towards the cofactor binding site of NSD1 than the sinefungin. Our data validates NSD1 as a cancer drug target and provides promising structures that can be utilized for further lead optimization and rational drug design to open new gateways in the field of cancer therapeutics.</p><p><strong>Graphical abstract: </strong></p><p><strong>Supplementary information: </strong>The online version contains supplementary material available at 10.1007/s40203-023-00158-0.</p>","PeriodicalId":13380,"journal":{"name":"In Silico Pharmacology","volume":"11 1","pages":"21"},"PeriodicalIF":0.0,"publicationDate":"2023-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10421842/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10052316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In-silico identification of small molecule benzofuran-1,2,3-triazole hybrids as potential inhibitors targeting EGFR in lung cancer via ligand-based pharmacophore modeling and molecular docking studies.","authors":"Sunil Kumar, Iqra Ali, Faheem Abbas, Nimra Khan, Manoj K Gupta, Manoj Garg, Saroj Kumar, Deepak Kumar","doi":"10.1007/s40203-023-00157-1","DOIUrl":"10.1007/s40203-023-00157-1","url":null,"abstract":"<p><p>Lung cancer is one of the most common and deadly types of cancer worldwide, and the epidermal growth factor receptor (EGFR) has emerged as a promising therapeutic target for the treatment of this disease. In this study, we designed a library of 1840 benzofuran-1,2,3-triazole hybrids and conducted pharmacophore-based screening to identify potential EGFR inhibitors. The 20 identified compounds were further evaluated using molecular docking and molecular dynamics simulations to understand their binding interactions with the EGFR receptor. In-silico ADME and toxicity studies were also performed to assess their drug-likeness and safety profiles. The results of this study showed the benzofuran-1,2,3-triazole hybrids BENZ-0454, BENZ-0143, BENZ-1292, BENZ-0335, BENZ-0332, and BENZ-1070 dock score of - 10.2, - 10, - 9.9, - 9.8, - 9.7, - 9.6, while reference molecule - 7.9 kcal/mol for EGFR (PDB ID: 4HJO) respectively. The molecular docking and molecular dynamics simulations revealed that the identified compounds formed stable interactions with the active site of the receptor, indicating their potential as inhibitors. The in-silico ADME and toxicity studies suggested that the compounds had good pharmacokinetic and safety profiles, further supporting their potential as therapeutic agents. Finally, performed DFT studies on the best-selected ligands to gain further insights into their electronic properties. The findings of this study provide important insights into the potential of benzofuran-1,2,3-triazole hybrids as promising EGFR inhibitors for the treatment of lung cancer. Overall, this study provides a valuable starting point for the development of novel EGFR inhibitors with improved efficacy and safety profiles.</p><p><strong>Graphical abstract: </strong></p><p><strong>Supplementary information: </strong>The online version contains supplementary material available at 10.1007/s40203-023-00157-1.</p>","PeriodicalId":13380,"journal":{"name":"In Silico Pharmacology","volume":"11 1","pages":"20"},"PeriodicalIF":0.0,"publicationDate":"2023-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10412522/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9998940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>In silico</i> studies on the phytochemical components of <i>Lagenaria siceraria</i> targeting aromatase receptors against breast cancer.","authors":"Saptarshi Samajdar, Prasenjit Mondal","doi":"10.1007/s40203-023-00155-3","DOIUrl":"10.1007/s40203-023-00155-3","url":null,"abstract":"<p><p>In India, breast cancer is the most common cause of mortality for women and has the potential to spread to other body organs. As a transcription factor, interactions with the estrogen receptor (ER) alpha are primarily responsible for the development of malignant tumors. Aromatase inhibitors are the most often used treatment for ER(+) breast cancer. Various synthetic compounds have been developed over the years to block the aromatase receptor, however, the majority of them are hazardous and cause multidrug resistance. So, combating these natural drugs can be prioritized. The current study was conducted to investigate the anticancer potential of <i>Lagenaria siceraria</i> phytoconstituents against breast cancer target protein (PDB ID: 3EQM) based on a literature review. In this study, 34 <i>Lagenaria siceraria</i> ligands were chosen, and the structure of the human aromatase receptor was acquired from the protein data bank. For those natural chemicals, molecular docking, drug-likeness, toxicity, and molecular dynamics were used to evaluate and analyse their anti-breast cancer activity. Five substances, 2,3-Diphenyl quinoxaline, 17-Acetoxy pregnolone, Benzyl-d-glucoside, Ergostenol acetate, and Stigmast-7-en-3-ol, shown higher binding affinity than Tamoxifen, signaling their potential use in breast cancer treatment.</p>","PeriodicalId":13380,"journal":{"name":"In Silico Pharmacology","volume":"11 1","pages":"19"},"PeriodicalIF":0.0,"publicationDate":"2023-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10387019/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10277182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of conserved multi-epitopes based hybrid vaccine against SARS-CoV-2 variants: an immunoinformatic approach.","authors":"Allah Rakha Yaseen, Muhammad Suleman, Abdul Salam Qadri, Ali Asghar, Iram Arshad, Daulat Munaza Khan","doi":"10.1007/s40203-023-00156-2","DOIUrl":"10.1007/s40203-023-00156-2","url":null,"abstract":"<p><p>The world has faced unprecedented disruptions like global quarantine and the COVID-19 pandemic due to SARS-CoV-2. To combat these unsettling situations, several effective vaccines have been developed and are currently being used. However, the emergence of new variants due to the high mutation rate of SARS-CoV-2 challenges the efficacy of existing vaccines and has highlighted the need for novel vaccines that will be effective against various SARS-CoV-2 variants. In this study, we exploited the four structural proteins of SARS-CoV-2 to execute a potential multi-epitope vaccine against SARS-CoV-2 and its variants. The vaccine was designed by utilizing the antigenic, non-toxic, and non-allergenic B-cell and T-cell epitopes, which were selected from conserved regions of viral proteins. To build a vaccine construct, epitopes were connected through different linkers and an adjuvant was also attached at the start of the construct to enhance the immunogenicity and specificity of the epitopes. The vaccine construct was then screened through the aforementioned filters and it scored 0.6019 against the threshold of 0.4 on VexiJen 2.0 which validates its antigenicity. Toll-like receptors (i.e., TLR2, TLR3, TLR4, TLR5, and TLR8) and vaccine construct were docked by Cluspro 2.0, and TLR8 showed strong interaction with construct having a maximum negative binding energy of - 1577.1 kCal/mole. C-IMMSIM's immune simulations over three doses of the vaccine and iMODS' molecular dynamic simulations were executed to assess the reliability of the docked complexes. The stability of the vaccine construct was evaluated through the physicochemical analyses and the findings suggested that the manufactured vaccine is stable under a wide range of circumstances and can trigger immune responses against various SARS-CoV-2 variants (due to conserved epitopes). However, to strengthen the formulation of the vaccine and assess its safety and effectiveness, additional investigations and studies are required to support the computational data of this research at <i>in-vitro</i> and <i>in-vivo</i> levels.</p><p><strong>Supplementary information: </strong>The online version contains supplementary material available at 10.1007/s40203-023-00156-2.</p>","PeriodicalId":13380,"journal":{"name":"In Silico Pharmacology","volume":"11 1","pages":"18"},"PeriodicalIF":0.0,"publicationDate":"2023-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10374517/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10276630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>In silico</i> analysis of sporozoite surface antigen 1 of <i>Theileria annulata</i> (TaSPAG1) for multi-epitope vaccine design against theileriosis.","authors":"Mojtaba Azimi-Resketi, Mehdi Akbari, Saeed Heydaryan, Amirreza Eftekhari, Javad Balali, Morteza Shams, Dariush Sargazi","doi":"10.1007/s40203-023-00153-5","DOIUrl":"10.1007/s40203-023-00153-5","url":null,"abstract":"<p><p>Tropical theileriosis is a protozoan infection caused by <i>Theileria annulata</i>, which significantly affects cattle worldwide. This study was aimed to analyze the TaSPAG1 protein and design a novel multi-epitope vaccine candidate. Online tools were employed for the prediction of Physico-chemical properties, antigenicity, allergenicity, solubility, transmembrane domains and signal peptide, posttranslational modification (PTM) sites, secondary and tertiary structures as well as intrinsically disordered regions, followed by identification and screening of potential linear and conformational B-cell epitopes and those peptides having affinity to bind bovine major histocompatibility complex class I (MHC-I) molecules. Next, a multi-epitope vaccine construct was designed and analyzed. This 907-residue protein was hydrophilic (GRAVY: -0.399) and acidic (pI: 5.04) in nature, with high thermotolerance (aliphatic: 71.27). Also, 5 linear and 12 conformational B-cell epitopes along with 8 CTL epitopes were predicted for TaSPAG1. The 355-residue vaccine candidate had a MW of about 35 kDa and it was antigenic, non-allergenic, soluble and stable, which was successfully interacted with cattle MHC-I molecule and finally cloned into the pET28a(+) vector. Further wet studies are required to assess the vaccine efficacy in cattle.</p><p><strong>Supplementary information: </strong>The online version contains supplementary material available at 10.1007/s40203-023-00153-5.</p>","PeriodicalId":13380,"journal":{"name":"In Silico Pharmacology","volume":"11 1","pages":"16"},"PeriodicalIF":0.0,"publicationDate":"2023-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10356686/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9855555","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}